• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Propanc Biopharma, Inc. - Common Stock (OP:PPCB)

10.40 UNCHANGED
Last Price Updated: 3:35 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Propanc Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
April 08, 2024
From Propanc Biopharma
Via Business Wire
Propanc Biopharma to Host Corporate Update Call Highlighting Recent Progress and Positive Results from Compassionate Use Study
February 22, 2024
From Propanc Biopharma, Inc
Via Business Wire
Propanc Biopharma Receives Certificate of Grant for PRP Foundation Patent from Canadian Intellectual Property Office
January 16, 2024
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Engages Boutique Advisory Firm to Identify Strategic Investment Opportunities
December 18, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
December 13, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells
November 07, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia
August 15, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030
July 25, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads
July 13, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors
July 05, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Provides Shareholder Update
June 22, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America
May 23, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Announces Reverse Stock Split
May 22, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer
March 28, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells
March 16, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)
January 11, 2023
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén
December 15, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer
November 30, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer
November 15, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma, Inc. (PPCB) Featured in Virtual Coverage of the Sidoti & Company Micro-Cap Investor Conference
November 04, 2022
Via Investor Brand Network
Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference
October 26, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17
October 12, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027
September 29, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Provides Shareholder Update
September 13, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment
September 08, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery Program
August 23, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office
August 16, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada
August 03, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade
July 28, 2022
From Propanc Biopharma, Inc.
Via Business Wire
Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program
July 19, 2022
From Propanc Biopharma, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+7.15 (3.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap